Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Engineering better chimeric antigen receptor T cells
Hao Zhang, Pu Zhao, He Huang
Experimental Hematology and Oncology (2020) Vol. 9, Iss. 1
Open Access | Times Cited: 85

Showing 1-25 of 85 citing articles:

Combination strategies to maximize the benefits of cancer immunotherapy
Shaoming Zhu, Tian Zhang, Lei Zheng, et al.
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 433
Nanocomplex‐Mediated In Vivo Programming to Chimeric Antigen Receptor‐M1 Macrophages for Cancer Therapy
Mikyung Kang, Seong Ho Lee, Miji Kwon, et al.
Advanced Materials (2021) Vol. 33, Iss. 43
Closed Access | Times Cited: 129
Claudin18.2 is a novel molecular biomarker for tumor-targeted immunotherapy
Weijie Cao, Haizhou Xing, Yingmei Li, et al.
Biomarker Research (2022) Vol. 10, Iss. 1
Open Access | Times Cited: 103
The current landscape of CAR T-cell therapy for solid tumors: Mechanisms, research progress, challenges, and counterstrategies
Amin Daei Sorkhabi, Leila Mohamed Khosroshahi, Aila Sarkesh, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 102
Targeting senescent cells with NKG2D-CAR T cells
Yushuang Deng, Avadh Kumar, Kan Xie, et al.
Cell Death Discovery (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 20
Chimeric Antigen Receptor-Engineered Natural Killer (CAR NK) Cells in Cancer Treatment; Recent Advances and Future Prospects
Reza Elahi, Amir Hossein Heidary, Kaveh Hadiloo, et al.
Stem Cell Reviews and Reports (2021) Vol. 17, Iss. 6, pp. 2081-2106
Open Access | Times Cited: 64
Strategies to enhance CAR-T persistence
Yue Liu, Lingna An, Ruihao Huang, et al.
Biomarker Research (2022) Vol. 10, Iss. 1
Open Access | Times Cited: 53
Emerging Trends in Immunotherapy for Cancer
Alok Mishra, Amjad Ali, Shubham Dutta, et al.
Diseases (2022) Vol. 10, Iss. 3, pp. 60-60
Open Access | Times Cited: 46
Cytokines as an important player in the context of CAR-T cell therapy for cancer: Their role in tumor immunomodulation, manufacture, and clinical implications
Caio Raony Farina Silveira, Amanda Cristina Corveloni, Sâmia Rigotto Caruso, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 46
TCR engineered T cells for solid tumor immunotherapy
Yikai Zhang, Zhipeng Liu, Wei Wei, et al.
Experimental Hematology and Oncology (2022) Vol. 11, Iss. 1
Open Access | Times Cited: 43
Inhibition of Calcium Signaling Prevents Exhaustion and Enhances Anti‐Leukemia Efficacy of CAR‐T Cells via SOCE‐Calcineurin‐NFAT and Glycolysis Pathways
Mi Shao, Xinyi Teng, Xin Guo, et al.
Advanced Science (2022) Vol. 9, Iss. 9
Open Access | Times Cited: 42
Non‐coding RNAs in cancer immunotherapy: Predictive biomarkers and targets
Murad Alahdal, Eyad Elkord
Clinical and Translational Medicine (2023) Vol. 13, Iss. 9
Open Access | Times Cited: 28
Nanoparticle-Based Chimeric Antigen Receptor Therapy for Cancer Immunotherapy
Seungyong Shin, Pyunghwajun Lee, Jieun Han, et al.
Tissue Engineering and Regenerative Medicine (2023) Vol. 20, Iss. 3, pp. 371-387
Open Access | Times Cited: 24
Potential and pitfalls of repurposing the CAR-T cell regimen for the treatment of autoimmune disease
Andrea R. Daamen, Peter E. Lipsky
Annals of the Rheumatic Diseases (2024) Vol. 83, Iss. 6, pp. 696-699
Closed Access | Times Cited: 14
Evolving understanding of autoimmune mechanisms and new therapeutic strategies of autoimmune disorders
Yi Song, Jian Li, Yuzhang Wu
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 13
Particle-Based Artificial Antigen-Presenting Cell Systems for T Cell Activation in Adoptive T Cell Therapy
Fei Hou, Zichao Guo, M. Ho, et al.
ACS Nano (2024) Vol. 18, Iss. 12, pp. 8571-8599
Closed Access | Times Cited: 11
TOX as a potential target for immunotherapy in lymphocytic malignancies
Chaofeng Liang, Shuxin Huang, Yujie Zhao, et al.
Biomarker Research (2021) Vol. 9, Iss. 1
Open Access | Times Cited: 48
Understanding CAR T cell-tumor interactions: Paving the way for successful clinical outcomes
Felix Korell, Trisha R. Berger, Marcela V. Maus
Med (2022) Vol. 3, Iss. 8, pp. 538-564
Open Access | Times Cited: 38
Preclinical Evaluation of CAR T Cell Function: In Vitro and In Vivo Models
Xiaohui Si, Lu Xiao, Christine E. Brown, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 6, pp. 3154-3154
Open Access | Times Cited: 37
Phenotypic Composition of Commercial Anti-CD19 CAR T Cells Affects In Vivo Expansion and Disease Response in Patients with Large B-cell Lymphoma
Chiara Monfrini, Federico Stella, Vanessa Aragona, et al.
Clinical Cancer Research (2022) Vol. 28, Iss. 15, pp. 3378-3386
Open Access | Times Cited: 33
Site-specific transgene integration in chimeric antigen receptor (CAR) T cell therapies
Hamed Dabiri, Pooria Safarzadeh Kozani, Mahdi Habibi‐Anbouhi, et al.
Biomarker Research (2023) Vol. 11, Iss. 1
Open Access | Times Cited: 12
Chimeric Antigen Receptor T-Cell Therapy in Lung Cancer: Potential and Challenges
Bufan Xiao, Jingtao Zhang, Yuge Zhu, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 39
Development of CAR T Cell Therapy in Children—A Comprehensive Overview
Michael Boettcher, Alexander Joechner, Ziduo Li, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 8, pp. 2158-2158
Open Access | Times Cited: 25
Past, Present, and a Glance into the Future of Multiple Myeloma Treatment
Weam Othman Elbezanti, Kishore B. Challagundla, Subash C. Jonnalagadda, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 3, pp. 415-415
Open Access | Times Cited: 16
Pre-clinical validation of a pan-cancer CAR-T cell immunotherapy targeting nfP2X7
Veronika Bandara, Jade Foeng, Batjargal Gundsambuu, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 14
Page 1 - Next Page

Scroll to top